Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo.

Kim EY, Liu Y, Akintujoye OM, Shyam K, Grove TA, Sartorelli AC, Rockwell S.

Radiat Res. 2012 Sep;178(3):126-37. Epub 2012 Aug 3.

2.

Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.

Rockwell S, Liu Y, Seow HA, Ishiguro K, Baumann RP, Penketh PG, Shyam K, Akintujoye OM, Glazer PM, Sartorelli AC.

Int J Radiat Biol. 2012 Mar;88(3):277-85. doi: 10.3109/09553002.2012.638359. Epub 2011 Dec 20.

3.

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells.

Seow HA, Penketh PG, Shyam K, Rockwell S, Sartorelli AC.

Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9282-7. Epub 2005 Jun 17.

4.

Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.

Donnelly ET, Kelley M, Rockwell S.

Cancer Chemother Pharmacol. 2004 Jan;53(1):43-50. Epub 2003 Oct 22.

PMID:
14574460
5.

Interactions of BMS-181174 and radiation: studies with EMT6 cells in vitro and in solid tumors.

Rockwell S, Kelley M.

Radiother Oncol. 1996 Apr;39(1):65-71.

PMID:
8735495
6.
7.

A strategy for selective O(6)-alkylguanine-DNA alkyltransferase depletion under hypoxic conditions.

Penketh PG, Shyam K, Baumann RP, Ishiguro K, Patridge EV, Zhu R, Sartorelli AC.

Chem Biol Drug Des. 2012 Aug;80(2):279-90. doi: 10.1111/j.1747-0285.2012.01401.x. Epub 2012 May 23.

8.

Preclinical studies of porfiromycin as an adjunct to radiotherapy.

Rockwell S, Keyes SR, Sartorelli AC.

Radiat Res. 1988 Oct;116(1):100-13.

PMID:
3186923
9.

Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.

Keyes SR, Heimbrook DC, Fracasso PM, Rockwell S, Sligar SG, Sartorelli AC.

Adv Enzyme Regul. 1985;23:291-307.

PMID:
3934922
10.

Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.

Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E 3rd.

Semin Oncol. 1990 Feb;17(1 Suppl 3):18-32.

PMID:
2106164
11.

Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns.

Bizanek R, Chowdary D, Arai H, Kasai M, Hughes CS, Sartorelli AC, Rockwell S, Tomasz M.

Cancer Res. 1993 Nov 1;53(21):5127-34.

12.

Influence of phosphate and phosphoesters on the decomposition pathway of 1,2-bis(methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by Laromustine, KS119, and KS119W.

Penketh PG, Shyam K, Zhu R, Baumann RP, Ishiguro K, Sartorelli AC.

Chem Res Toxicol. 2014 May 19;27(5):818-33. doi: 10.1021/tx500004y. Epub 2014 Mar 24.

13.

Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines.

Shyam K, Penketh PG, Shapiro M, Belcourt MF, Loomis RH, Rockwell S, Sartorelli AC.

J Med Chem. 1999 Mar 11;42(5):941-6.

PMID:
10072691
14.
17.
18.
19.
20.

Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo.

Rockwell S, Keyes SR, Loomis R, Kelley M, Vyas DM, Wong H, Doyle TW, Sartorelli AC.

Cancer Commun. 1991 Jun;3(6):191-8.

PMID:
2049227
Items per page

Supplemental Content

Write to the Help Desk